AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
Executive Summary
AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.
You may also be interested in...
Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.
Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.